2017 Annual Meeting | C132 - Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man
| 01:00 PM - 01:25 PM | Speaker |
Discovery of Novel Therapeutic Agents for CNS Disorders: Target Selection and Discovery Process
Peter Lansbury, PhD |
| 01:25 PM - 01:50 PM | Speaker |
Entry of Novel Therapeutic Agents into Man
Jang-Ho J. Cha, MD, PhD |
| 01:50 PM - 02:15 PM | Speaker |
Beyond Small Molecules: Developing Biologic Therapies
Gary Starling, PhD |
| 02:15 PM - 02:40 PM | Speaker |
What Can Be Done to Increase Translational Success
Shai Silberberg, PhD |
| 02:40 PM - 03:00 PM | Q&A |
Questions and Answers
|
| Amy R. Brooks-Kayal, MD, FAAN | Dr. Brooks-Kayal has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for ABPN. Dr. Brooks-Kayal has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. Dr. Brooks-Kayal has stock in Johnson and Johnson. The institution of Dr. Brooks-Kayal has received research support from NINDS. |
| Jang-Ho J. Cha, MD, PhD | No disclosure on file |
| Peter Lansbury, PhD | No disclosure on file |
| Gary Starling, PhD | No disclosure on file |
| Shai Silberberg, PhD | No disclosure on file |